Search Results for “EU” – Page 16 – media

Gerresheimer to acquire Blitz LuxCo Sarl, for EUR 800 million

Gerresheimer Glas GmbH, an indirect subsidiary of Gerresheimer AG, has signed a purchase agreement with funds advised by Triton for the acquisition of Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group (Bormioli Pharma). The purchase price is based on a determined enterprise value of around EUR 800 million, which corresponds to an adj. EBITDA multiple of around 10 Bormioli Pharma, has 9 production sites in Europe. The Group generates revenues of around EUR 370 million and an adj. EBITDA margin of around 21 per cent. Bormioli Pharma has a complementary portfolio of pharmaceutical primary packaging made of glass and plastic, as well as closure solutions, accessories, and dispensing systems. With this acquisition, Gerresheimer strengthens its European footprint with additional production sites, especially in Southern Europe, and underpins its market position as a leading full-service provider and global partner for the pharmaceutical and biotech industries. The acquisition is ...
- Source: drugdu
- 117
- May 27, 2024
Focusing on intelligent pharmaceutical manufacturing, Nanchang, Jiangxi, promotes high-quality development of the biopharmaceutical industry

Recently, when I walked into the disposable medical supplies production workshop of Nanchang Ruiao Jucheng Biotechnology Co., Ltd. located in Nanchang Economic and Technological Development Zone, Jiangxi Province, I saw the workers on the intelligent production line skillfully carrying out product inspection, assembly, packaging and other tasks, and the scene was full of bustling production. It is understood that Nanchang Ruiao Jucheng Biotechnology Co., Ltd. is a high-tech enterprise specializing in biotechnology research, development and production . “At present, the company’s production orders have been scheduled until November, and the products are in short supply. In order to meet the production needs of orders, we have carried out targeted expansion by adding new production lines.” Zhou Bin, chairman of Nanchang Ruiao Jucheng Biotechnology Co., Ltd., introduced. At present, the company has built instrument production workshops and reagent production workshops, which can produce 100 flow cytometers and 5 million diagnostic kits ...
- Source: drugdu
- 83
- May 24, 2024
Coya Therapeutics Receives $5 Million Investment from the Alzheimer’s Drug Discovery Foundation

Don Tracy, Associate Editor Investment from the Alzheimer’s Drug Discovery Foundation (ADDF) aims to support the development of Coya 302, a therapeutic candidate for the treatment of frontotemporal dementia (FTD). Coya Therapeutics announced that it has received a $5 million strategic investment from the Alzheimer’s Drug Discovery Foundation (ADDF). According to the company, the investment consisted of 603,136 shares of stock at $8.29 per share. Coya intends to use the funding for supporting the development of Coya 302, its lead therapeutic candidate, mainly in an upcoming Phase II trial targeting frontotemporal dementia (FTD). Reportedly, the investment was made through a private placement under Section 4(a)(2) of the Securities Act of 1933 and Regulation D, aiming to file a registration statement with the SEC for resale of the securities.1 “We are grateful that a world-renowned organization like the ADDF has chosen to support our corporate mission as well as the clinical ...
- Source: drugdu
- 74
- May 22, 2024
European Commission Decision Is a Reprieve for PTC Therapeutics’ Rare Muscle Disease Drug

The PTC Therapeutics drug Translarna failed its confirmatory study in Duchenne muscular dystrophy. Analysts say the European Commission’s decision to not adopt the Committee on Medicinal Products for Human Use’s negative opinion on the drug is unusual, if not unprecedented. By Frank VinluanA PTC Therapeutics drug that failed a confirmatory study in the rare muscle-wasting disorder Duchenne muscular dystrophy may remain on the market in Europe for now. Regulators there took the rare step of declining to adopt a recommendation opposing renewal of the product’s marketing authorization. The PTC drug, Translarna, received conditional marketing authorization in 2014 based on Phase 2 data. The conditional nature of this pathway requires a company to seek annual renewals of the authorization until it generates the clinical data that supports a standard marketing authorization. In a placebo-controlled Phase 3 study, Translarna failed to achieve the main goal of showing a significant change according to ...
- Source: drugdu
- 71
- May 22, 2024
CNS-Focused Rapport Therapeutics Preps IPO to Back Phase 2-Ready Epilepsy Drug

Rapport Therapeutics’ lead program could offer more targeted epilepsy treatment compared to currently available anti-seizure medications, which introduce many side effects. The IPO will support plans to develop the oral small molecule in focal epilepsy as well as chronic pain and bipolar disorder. By Frank VinluanRapport Therapeutics, a young biotech company with technology from the labs of Johnson & Johnson, is now preparing to enter the public markets to finance clinical research for a lead program that could help patients whose epilepsy doesn’t respond to currently available anti-seizure medications. Rapport’s IPO paperwork filed with securities regulators late Friday does not yet specify how many shares it plans to offer and in what price range. IPO research firm Renaissance Capital has penciled in a $100 million placeholder figure for the proposed stock offering. The biotech company, which is headquartered in Boston and maintains additional office and lab space in San Diego, ...
- Source: drugdu
- 83
- May 21, 2024
AbbVie, Gilgamesh Pharmaceuticals Agree to Terms on a Collaboration to Develop Advanced Therapies for Psychiatric Disorders

The joint venture aims to address unmet needs in the treatment of mood and anxiety disorders through novel neuroplastogens.AbbVie and Gilgamesh Pharmaceuticals have announced a partnership focused on the development of therapies for psychiatric disorders. The collaboration seeks to leverage AbbVie’s experience in psychiatry and Gilgamesh’s research platform that focuses on neuroplastogens, which works to treat psychiatric conditions while minimizing adverse effects attributed to psychedelic compounds. According to the companies, the overall goal is to provide new opportunities in areas that haven’t provided manysolutions for patients with mood and anxiety disorders through the use of neuroplastogens. Under terms of the deal, AbbVie is expected to focus on future development and commercialization activities, while Gilgamesh will receive $65 million as an upfront payment. Upon the completion of specific milestones, including option fees and tiered royalties on net sales, Gilgamesh could potentially receive up to $1.95 billion.1 “Significant unmet need remains for ...
- Source: drugdu
- 108
- May 16, 2024
Hengrui Pharmaceuticals Innovative Drug SHR-2173 Injection for IgA Nephropathy Indication Approved for Clinical Use

Recently, Hengrui Pharmaceuticals’ subsidiary Guangdong Hengrui Pharmaceuticals Co., Ltd. received the Notice of Approval for Clinical Trial of Drugs approved by the State Drug Administration, approving SHR-2173 Injection, a Class 1 new drug, to carry out clinical trials for IgA nephropathy. At present, there is no similar drug to SHR-2173 on the market or in the clinical development stage at home and abroad. IgA nephropathy is a group of autoimmune glomerulonephritis characterized by IgA deposition in the glomerular mesangial area. Typical clinical manifestations can be seen in microscopic hematuria, and patients have a history of mucosal (e.g., upper respiratory tract, gastrointestinal tract) infections, which is the most common primary glomerulopathies worldwide, and also a major cause of chronic kidney disease (CKD) and renal failure. In China, IgA nephropathy accounts for 45% of primary glomerular diseases in China. There are geographical differences in the incidence of the disease, and the peak ...
- Source: drugdu
- 76
- May 16, 2024
Hengrui Pharmaceuticals’ HRS5580 for Injection for Prevention of Postoperative Nausea and Vomiting Approved for Clinical Trial

Recently, Hengrui Pharmaceuticals’ subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received the Approval Notice of Drug Clinical Trial issued by the State Drug Administration, which approved the company’s HRS5580 for injection to carry out clinical trials for the prevention of postoperative nausea and vomiting. Postoperative nausea and vomiting (PONV) mainly occurs within 24 hours after surgery, but can also be as long as 3~5 days, is one of the common complications of surgery. The incidence of PONV is estimated to be 20% to 37%, with a probability of up to 80% in high-risk patients. Nausea and vomiting can be a distressing experience for patients when combined with postoperative pain. The effectiveness of the current main clinical agents for the prevention of PONV for the prevention of vomiting after surgery needs to be improved, and the development of new therapeutic agents is urgently needed. HRS5580 for injection is an injectable agent independently ...
- Source: drugdu
- 112
- May 14, 2024
Otsuka Launches New Company to Commercialize Rejoyn, the First Digital Therapeutic for Depression

Otsuka Pharmaceutical is launching a subsidiary that will commercialize its digital therapeutic Rejoyn — as well as other digital therapeutics and connected health products down the line. Last month, Rejoyn became the first FDA-cleared digital therapeutic for patients with depression.Last month, an app named Rejoyn became the first FDA-cleared prescription digital therapeutic for patients with major depressive disorder. The app, which changes users’ behavior through various lessons and exercises, was developed by Otsuka Pharmaceutical and Click Therapeutics. On Monday, Otsuka announced that it is launching a new data and technology-focused subsidiary that will commercialize Rejoyn — as well as other digital therapeutics and connected health products down the line. The new company — named Otsuka Precision Health — is a subsidiary of Otsuka America, which is a subsidiary of Tokyo-based Otsuka Pharmaceutical. Rejoyn is a six-week program intended to be used alongside antidepressants. The app leverages clinically validated cognitive emotional ...
- Source: drugdu
- 111
- May 10, 2024
FDA Approves Two of Scientia Vascular’s Neurovascular Catheters

Don Tracy, Associate Editor The catheters approved by the FDA include the Plato 17, a DMSO-compatible microcatheter, and the Socrates 38, an aspiration catheter specifically designed for treating ischemic strokes. Scientia Vascular announced that the FDA has approved two of its neurovascular catheters. According to the company, the Plato 17 microcatheter offers physicians the ability to control and stabilize neurovascular applications and is also DMSO compatible. The Socrates 38, which is currently in a limited market release, is an aspiration catheter for treating ischemic strokes. Scientia stated that the approvals mark a significant advancement in its medical technology portfolio.1 “Our FDA clearance is a significant milestone for Scientia Vascular. By applying proven microfabrication technology to catheters and designing our access and treatment devices for efficiency when used together, we’re providing physicians the next generation of neurovascular access tools.” said John Lippert, CEO, Scientia Vascular, in a press release. “I am ...
- Source: drugdu
- 80
- May 9, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.